Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

Lifecare ASA: Updated company presentation

Lifecare

Bergen, Norway, 23 April 2025 - Lifecare ASA (LIFE), a medtech company developing next generation continuous glucose monitoring (CGM) solutions for diabetes management, today publishes an updated company presentation articulating the company’s long-term value creation opportunity.

The presentation is attached and available at: https://lifecare.no/investor/

Key highlights from the presentation:

Diabetes is a trillion-dollar global healthcare challenge

  • CGMs the fastest growing diabetes tech segment, representing a USD 30 billion market opportunity
  • Within CGMs, implantable solutions represent a USD 5 billion potential market

Strong value drivers in place 2025-2028

  • Set to capitalize on “second mover” advantage, leveraging first mover regulatory approvals in the US
  • Capital efficient path to commercialization with partner-led go-to-market strategy and minimal additional R&D
  • Near-term value inflection points including veterinary market launch late 2025, CE mark in 2026, and European human market launch in 2027

Significant value creation potential

  • Peak revenue potential of USD 1 billion + on realistic market assumptions
  • Revenue sustainable at high levels long-term assuming conservative market share in a growing market
  • EBITDA margin of 35%+

About us
Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is referred to as "Sencell" and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

Attachments
Lifecare ASA: Updated company presentation
Lifecare Company Presentation April 2025

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team